InicioALNOV • EPA
add
Novacyt
Cierre anterior
0,67 €
Intervalo diario
0,66 € - 0,69 €
Intervalo anual
0,45 € - 1,59 €
Cap. bursátil
47,90 M EUR
Volumen medio
458,67 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
EPA
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (GBP) | jun 2024info | Cambio interanual |
|---|---|---|
Ingresos | 5,16 M | 209,13 % |
Gastos operativos | 7,92 M | 92,89 % |
Ingresos netos | -8,85 M | -112,01 % |
Margen de beneficio neto | -171,47 | 31,41 % |
Beneficios por acción | — | — |
EBITDA | -12,02 M | -324,07 % |
Tipo impositivo efectivo | 1,22 % | — |
Balance general
Activos totales
Responsabilidades totales
| (GBP) | jun 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 32,95 M | -59,69 % |
Activos totales | 99,40 M | -24,78 % |
Responsabilidades totales | 28,99 M | 16,70 % |
Patrimonio total | 70,41 M | — |
Acciones en circulación | 70,63 M | — |
Precio-valor contable | 0,67 | — |
Rentabilidad económica | -36,30 % | — |
Retorno sobre capital | -43,18 % | — |
Flujo de caja
Variación neta del flujo de caja
| (GBP) | jun 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -8,85 M | -112,01 % |
Efectivo de operaciones | -4,54 M | -59,67 % |
Efectivo de inversión | -566,50 mil | -212,18 % |
Efectivo de financiación | -430,50 mil | -61,24 % |
Variación neta del flujo de caja | -5,56 M | -112,16 % |
Flujo de caja libre | -17,73 M | -943,16 % |
Información sobre la empresa
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Director ejecutivo
Fundación
2006
Sitio web
Empleados
240
